Back to Search
Start Over
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
- Source :
- Acta pharmacologica Sinica. 43(4)
- Publication Year :
- 2020
-
Abstract
- HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianostat alone and in combination with bortezomib in the treatment of multiple myeloma (MM), as well as preliminary first-in-human findings from an ongoing phase 1a study. Bisthianostat dose dependently induced acetylation of tubulin and H3 and increased PARP cleavage and apoptosis in RPMI-8226 cells. In RPMI-8226 and MM.1S cell xenograft mouse models, oral administration of bisthianostat (50, 75, 100 mg·kg
Details
- ISSN :
- 17457254
- Volume :
- 43
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Acta pharmacologica Sinica
- Accession number :
- edsair.pmid..........06ddd98b662e86fdd03446bc8b7654c9